SUSY Ward identities in N=1 SYM theory on the lattice

The SUSY Ward identities (WIs) for the N=1 SU(2) SUSY Yang Mills theory discretized on the lattice with Wilson fermions (gluinos) are considered. The study is performed in the framework of a Monte Carlo simulation of the model with light dynamical gluinos. The renormalization and mixing constants of the lattice SUSY current $Z_S$ and $Z_T$ and the additively renormalized gluino mass $m_S$ are unknown parameters of the SUSY WIs. Using suitable on-shell combinations of the WIs, the ratios $Z_T/Z_S$ and $m_S/Z_S$ are determined non-perturbatively at one value of the coupling constant $g_0$ and two values of the hopping parameter $\kappa$.Comment: Lattice 2000 (Supersymmetry), 4 pages, 2 figure

On the 1-loop lattice perturbation theory of the supersymmetric Ward identities

The one loop corrections to the supersymmetric Ward identities (WIs) in the discretized N=1 SU(2) supersymmetric Yang-Mills theory can be investigated by means of lattice perturbation theory. The supersymmetry (SUSY) is explicitly broken by the lattice discretization as well as by the introduction of Wilson fermions. However, the renormalization of the supercurrent can be carried out in a scheme that restores the nominal continuum WIs. We present our work in progress which is concerned with the 1-loop renormalization of the local supercurrent, i.e. with the perturbative computation of the corresponding renormalization constants and mixing coefficients.Comment: Lattice 2000 (Supersymmetry), 4 pges, 2 figure

Lattice supersymmetric Ward identities

SUSY Ward identities for the N=1 SU(2) SUSY Yang-Mills theory are studied on the lattice in a non-perturbative numerical approach. As a result a determination of the subtracted gluino mass is obtained.Comment: 3 pages, 2 figures, Lattice2001(higgssusy

SUSY Ward identities in 1-loop perturbation theory

We present preliminary results of a study of the supersymmetric (SUSY) Ward identities (WIs) for the N=1 SU(2) SUSY Yang-Mills theory in the context of one-loop lattice perturbation theory. The supersymmetry on the lattice is explicitly broken by the gluino mass and the lattice artifacts. However, the renormalization of the supercurrent can be carried out in a scheme that restores the nominal continuum WIs. The perturbative calculation of the renormalization constants and mixing coefficients for the local supercurrent is presented.Comment: Lattice2001(higgssusy); 3 page

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

Background: Cetuximab plus FOLFIRI improved overall survival compared with bevacizumab plus FOLFIRI in KRAS wild-type metastatic colorectal cancer (mCRC) in FIRE-3, but no corresponding benefit was found for progression-free survival. This analysis aimed to determine whether cetuximab improves response and survival versus bevacizumab among response-evaluable patients receiving first-line FOLFIRI for RAS wild-type mCRC and the effect of primary tumour side on outcomes. Methods: The intent-to-treat population included 593 patients with KRAS exon 2 wild-type mCRC. Further testing identified 400 patients with extended RAS wild-type disease; of these, 352 (88%) who received ≥3 cycles of therapy and had ≥1 post-baseline scan were evaluable for response and constituted the per-protocol population (169 cetuximab and 183 bevacizumab). Patients received 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) with either weekly cetuximab or biweekly bevacizumab given on day 1 of each 14-day cycle until response, progression or toxicity occurred. The primary endpoint was the objective response rate (ORR) in the per-protocol population. Secondary endpoints included overall survival (OS) and progression-free survival (PFS). The effect of primary tumour location was evaluated. Results: Median OS in the RAS wild-type population was 31 vs 26 months in the cetuximab and bevacizumab groups, respectively (HR 0.76, P = 0.012). In the per-protocol population, outcomes favoured cetuximab for ORR (77% vs 65%, P = 0.014) and median OS (33 vs 26 months, HR 0.75, P = 0.011), while PFS was comparable between groups. The advantage of cetuximab over bevacizumab occurred only in patients with left-sided primary tumours. Conclusions: FOLFIRI plus cetuximab resulted in a significantly higher ORR and longer OS compared to FOLFIRI plus bevacizumab among patients with left-sided tumours. The superior response associated with cetuximab may particularly benefit patients with symptomatic tumours or borderline-resectable metastases. CLINICALTRIALS.Gov identifier: NCT00433927